<DOC>
	<DOCNO>NCT02804399</DOCNO>
	<brief_summary>The purpose study estimate effect rifampin single dose PK PF-06463922 .</brief_summary>
	<brief_title>A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers</brief_title>
	<detailed_description>This Phase 1 , open-label , 2-period , 2-treatment , fixed-sequence , cross-over study approximately 12 healthy subject employ administration single oral dose PF-06463922 fast state alone , multiple dose rifampin 600 mg day estimate effect multiple dose rifampin single dose PK PF-06463922 .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Healthy female subject nonchildbearing potential and/or male subject , time screening , age 18 55 year , inclusive Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease Any condition possibly affect drug absorption Positive urine drug screen History HIV , Hep B Hep C History regular alcohol consumption History cardiac arrhythmia , history AV block , history symptomatic bradycardia , history QTc prolongation History pancreatitis hyperlipidemia , elevate lipase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>rifampin</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>PF-06463922</keyword>
	<keyword>drug interaction</keyword>
</DOC>